Swiss National Bank Cel Sci Corp Transaction History

Swiss National Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$2.58 - $4.99 $262,386 - $507,483	-101,700 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$3.93 - $7.7 $27,510 - $53,900	7,000 Added 7.39%	101,700 $400,000
Q4 2021 Feb 08, 2022	BUY	$7.1 - $12.82 $38,340 - $69,228	5,400 Added 6.05%	94,700 $672,000
Q2 2021 Aug 06, 2021	BUY	$8.68 - $27.49 $54,684 - $173,187	6,300 Added 7.59%	89,300 $775,000
Q4 2020 Feb 05, 2021	BUY	$11.05 - $16.62 $22,100 - $33,240	2,000 Added 2.47%	83,000 $968,000
Q3 2020 Nov 09, 2020	BUY	$11.69 - $14.54 $18,704 - $23,264	1,600 Added 2.02%	81,000 $1.03 Million
Q2 2020 Aug 05, 2020	BUY	$9.75 - $17.6 $774,150 - $1.4 Million	79,400 New	79,400 $1.19 Million

6.95M

38.3K

184K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $18.2M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.